ZBIO - Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc. Common Stock Logo

ZBIO - Zenas BioPharma, Inc. Common Stock

https://zenasbio.com
Buy Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Range-Bound
As of 2025-09-09 (Snapshot)

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. The company is headquartered in Waltham, Massachusetts.

52W High
$26.25
52W Low
$5.83
MA Status:
50D: Above 200D: Above
Beta (~1 neutral, <0.9 lower risk)
N/A
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
N/A
EV/Revenue (<3 favorable)
39.43
P/S (TTM) (<3 favorable)
57.58
P/B (<3 favorable)
3.60
Ownership
Institution‑heavy
Source: Overview
Insiders (1–5% typical)
21.06%
Institutions (25–75% balanced)
78.01%
Shares Outstanding
42,110,300
Float
21,072,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
15,000,000
Gross Profit (TTM)
-145,628,992
EPS (TTM)
-12.29
Profit Margin (>10% good)
N/A
Operating Margin (TTM) (higher better)
-12.61%
ROE (TTM) (>15% strong)
-0.88%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
N/A
Momentum
Bearish momentum
Value
0.7046
Previous
0.7318
Trend
Falling
Signal Cross
No cross
As of
Sep. 04, 2025